In conclusion, our study has introduced a refined immunohistochemical scoring system for CDX2 expression that considers the inherent heterogeneity of colon tumors—a detail often missed by conventional immunohistochemical scoring systems. This evidence concerns the gene CDX2 and colonic neoplasm.